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Background: It has been reported that patients with SCD do have an abnormal coagulation profile. Coagulopathy
is thought to be one of the key factors that contribute to the vaso-occlusive crisis that characterises sickle cell
disease (SCD). In this study, we investigated whether Sudanese sickle cell patients have an abnormal coagulation
profile. In addition, the effect of treatment with either omega-3 fatty acids or hydroxyurea on coagulation profile
was assessed.
Methods: Homozygous SCD patients untreated (n = 52), omega-3 treated (n = 44), hydroxyurea (HU) treated
(n = 8) and healthy (HbAA) controls (n = 52) matched for age (4–20 years), gender and socioeconomic status
were enrolled. Patients on omega-3 fatty acids, according to age, received one to four capsules containing 277.
8 mg DHA and 39.0 mg eicosapentnoic. Patients on Hydroxyurea were in on dosage more than 20 mg/kg/day.
The steady state levels of the coagulation parameters and the effect of the treatments with either HU or omega-3
fatty acids on markers of coagulation were investigated.
Results: Compared to the healthy controls, treated and untreated HbSS patients had lower hemoglobin, plasma
Protein C, proteins S and higher white blood cell count (WBC), platelets count (PLTs) and plasma D-dimer
levels,(p < 0.05). In comparison to untreated HbSS, treatment with neither omega-3 nor HU had effect on the
WBC, plasma proteins C and S, (p > 0.05). HU treated group had a lower PLTs count compared to HbSS untreated
group (p < 0.5). The prothrombin and activated partial thromboplastin times and international normalized ratio
(INR) of untreated patients are significantly higher than n-3 treated, HU-treated patients and health controls,
(p < 0.05). Patients treated with omega-3 had lowered D-dimer levels in comparison to HU-treated and untreated
HbSS patients, (p < 0.001).
Conclusion: This study provides evidence that Sudanes patients have abnormal coagulation profile and treatment
with either HU or omega-3 fatty acids might partially ameliorate SCD-associated chronic coagulopathic state.
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Chronic hypercoagulable or prothrombotic state is
generally known to be one of the factors that contrib-
ute to vaso-occlusion and progressive end-organ dam-
age in sickle cell disease (SCD) [1, 2]. Studies on SCD
patients at steady state patients from different geo-
graphic and demographic origins have shown elevated
level of markers of coagulation activation [3, 4], and
decreased natural anticoagulant proteins [5, 6]. Agents
that physiologically activate platelets and coagulation
in vivo include adenosine diphosphate (ADP), colla-
gen, epinephrine, thrombin, serotonin, arachidonic
acid and thromboxane A2 [7]. Interestingly, blood cell
membranes of patients with SCD have an abnormal
fatty acid profile which is characterised by low levels
of omega-3, namely eicosapentaenoic (EPA) and doco-
sahexaenoic acids (DHA), and a high level of omega-6,
particularly arachidonic acid (AA) [8, 9]. A high intake
of omega-3 fatty acids is inversely associated with
thromboxane level and prothrombotic activity [10, 11].
Consequently, it has been postulated that regular intake of
n-3 fatty acids in patients with SCD may modulate
markers of coagulation.
On the other hand, Hydroxyurea (hydroxycarbamide)
is currently the only approved drug to prevent the acute
complications of the disease [12], and has several well-
defined beneficial effects that might involve mitigation
of the hypercoagulability state in patients with SCD [13].
In this study we investigated whether (1) Sudanese sickle
cell patients have an abnormal profile of coagulation pa-
rameters; (2) the coagulation parameter are modified by
omega-3 fatty acids or hydroxyurea.
Methods
Subjects
In this study, steady state homozygous sickle cell pa-
tients (HbSS) on high DHA omega-3 treatment (n = 44),
hydroxyurea treatment HbSS (HU, n = 8), steady HbSS
patients not treated either with HU or omega-3 fatty
acids (n = 52) controls and healthy sibling controls
(HbAA, n = 52), matched one to one by age (4–20 years),
gender and socioeconomic status were included. “Steady
state” is defined as being free from acute painful crisis or
other medical condition for at least one month before
the enrolment. The patients and healthy controls, who
were mostly siblings of the patients, were enrolled from
Abnaof Paediatric Hospital, Khartoum, Sudan, between
February and May 2014. We selected the patients’
healthy HbAA siblings as controls in order to minimise
the potential effect of dietary background and genetic
factors on the variables under investigation. Haemoglo-
bin phenotypes were confirmed using cellulose acetate
electrophoresis at pH 8.5. The exclusion criteria for par-
ticipation in the study were other chronic disorder andconditions (defined as the one that lasting 3 months or
more), blood transfusion in the previous four-months.
The patients on n-3 fatty acids received a daily dosage of
one, two, three or four capsules according to the patient’s
age (< 5), (5–10), (11–16) and (>17) years, respectively.
The n-3 capsule contains 277.8 mg docosahexaenoic
(DHA) and 39.0 mg eicosapentnoic (EPA) and (1.5 mg) of
vitamin E to prevent fatty acids peroxidation. The n-3
fatty acid group was on same dosage of n-3 fatty acids for
minimum of three years. The hydroxyurea group was
treated daily with a dose of 20 mg per kilogram body
weight orally for minimum of at least one year. The pa-
tients participated in this study were on regular folate sup-
plement. The healthy control subjects did not receive
folate or any other nutritional supplement.
The equation (n = (Zα/2 + Zβ)
2 *2*σ2 / d2) was employed
to calculate the sample size, and the assumption that the
mean difference of D-dimer between the omega-3 treated
and untreated patients 1 μg/ml compared to untreated.
The population variance was assumed to equal to 2 μg/ml.
To detect the assumed mean difference with 95% power
at a 5% significance level, minimum of 43 patients is re-
quired in each arm.Blood sample collection and processing
Blood was drawn under sterile conditions into EDTA
coated (2.5 ml) and tri-sodium citrate (2.5 ml) contain-
ing vacutainer tubes. The EDTA blood was used for
hematological tests. The citrate blood was immediately
fractionated into plasma and red blood cells by cold
centrifugation at 3000 rpm for 15 min. The resulting
top plasma layer was carefully siphoned off, without
contaminating with buffy coat, and transferred into an-
other tube and stored at–80 °C. The stored plasma was
subsequently used for the determination of coagulation
profile and anticoagulation proteins.Hematological parameters
Haemoglobin concentration (Hb), haematocrit (Ht), mean
corpuscular volume (MCV), mean corpuscular haemoglo-
bin (MCH), mean corpuscular haemoglobin concentration
(MCHC), total white blood cell count (TWBC), platelet
count (PLTs) and total red blood cell count were measured
with the use of Sysmex KX-21 N Automated Hematology
Analyzer (Sysmex Corporation, Kobe, Japan).Coagulation profile
Prothrombin time (PT) and activated partial thrombo-
plastin time (aPTT) were determined by an automated
micro-computer controlled coagulometer, DiaMed-CD2
(DIaMed, GmbH, Cressier, Switzerland). International
normalized ratio (INR) was also assessed.
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The concentration of D-dimer was measured by enzyme-
linked immune-sorbent assay using i-Chroma hsCRP
test kits and i-CHROMA Reader (BodiTech Med Inc.,
Gang-won do, Korea).
Anticoagulation proteins C and S
Proteins C and S concentrations were determined by
enzyme linked immune-sorbent assay kit (Asys Hitech
GmbH, Austria).
Data analysis
According to the parametric or non-parametric distribu-
tion, the data were expressed as mean ± SD or median
and interquartile range (IQR) as pertinent. The groups
were compared for haematological profile, coagulation
profile, anticoagulant proteins and D-dimer levels by
using one-way an ANOVA on ranks (Kruskal-Wallis H
test). When statistical differences were indicated, Dunn’s
non-parametric comparison for post-hoc tests were
obtained. The statistical significance was assumed at a
“p” value of less than 0.05. The data were analysed with
SPSS for Windows, Version 19 (SPSS Ltd., Surrey, UK).
Results
Demographic and haematological characteristics
The baseline demographic and haematological values of
the omega-3 fatty acid treated and untreated patients and
healthy controls were described in Table 1. The mean age
of the patients on HU was significantly higher than that of
the other three groups (p < 0.05).
Haematological parameters
The hematological values of the groups studied were shown
in Table 2. Apart from PLT count, neither treatment with
omega-3 nor HU resulted in significant change in haemato-
logical profile in comparison to HbSS untreated patients.
The haematological parameters MCV, MCH and MCHC
values of the patients and healthy controls were not differ-
ent (p > 0.05).Table 1 Baseline demographic and hematological characteristics












44 52 8 52
Male 22 28 6 28
Female 22 24 2 24
Age (years,
mean ± SD)
9.8 ± 2.9 10.8 ± 4.0 17.4 ± 0.9* 11.3 ± 4.0
*P < 0.05 hydroxyurea group compared with groupsCoagulation profile (PT, aPTT and INR)
In comparison with the healthy controls, the omega-3
fatty acid treated, HU-treated and untreated patients
had increased PT, aPTT and INR (p < 0.01, Table 3).
The omega-3 treated and, HU-treated patients had sig-
nificantly lower coagulation parameters when com-
pared with Untreated patients (p < 0.05, Table 3).
Plasma D-dimer levels
The healthy control subjects had a lower level of
plasma D-dimer concentration than the omega-3 fatty
acid treated, HU-treated and un-treated patients
(p < 0.001). The omega-3 fatty acid treated group com-
pared with HU-treated (Median = 1.14 (IQR = 0.74)
μg/ml vs Median = 2.33.0 (IQR = 3.17) μg/ml,
(p < 0.001)) and untreated (Median = 1.4 (IQR = 0.74)
μg/L vs Median = 1.75 (IQR = 1.16) μg/ml, (p < 0.001)
patients had a lower plasma D-dimer level. Patients
treated with HU had a higher levels of plasma D-dimer
compared to HbSS untreated (p < 0.01, Fig. 1).
Plasma proteins C and S levels
The untreated patients had reduced level of plasma pro-
tein C compared with the healthy controls (Median = 90.5
(IQR = 20.0) μg/mL, (p < 0.001). The omega-3 fatty acid
(Median = 60.5 (IQR = 19) μg/mL) and HU (Median = 59.5
(IQR = 13) μg/mL), (p > 0.05) treated and the untreated
(Median = 60.0 (IQR = 23.0) μg/mL) patients had compar-
able concentration of protein C (p > 0.05, Fig. 2).
Plasma protein S concentration was lower in the
treated (omega-3 and HU) and untreated patients than
in the healthy controls (Median = 139.5 (IQR = 28.0)
μg/mL, (p < 0.001)). There was no difference in protein
S level between the unntreated (Median = 42.5
(IQR = 18.0) μg/mL), omega-3 treated (Median = 45.5
(IQR = 14.0) μg/mL) and HU-treated (Median = 40.5
(IQR = 11) μg/mL) patients (p > 0.05, Fig. 3).
Discussion
Hydroxyurea, which is a cytotoxic, antimetabolic and anti-
neoplastic agent, is the only disease-modifying therapy ap-
proved for sickle cell disease [14]. Hydroxyurea has been
shown to be partially effective in reducing the frequency
of vaso-occlusive events; but, there is no evidence that it
prevents organ damage [15]. One of the factors which re-
stricts HU usage is that it undergoes renal clearance, and
hence there is a need for careful dose adjustment and
close monitoring of myelotoxicity in individuals with renal
impairment [16]. This vital requirement is hardly possible
to undertake in most developing countries where SCD is
highly prevalent because of lack of functional facilities and
expertise. Therefore, there is a need for safe, effective and
easily manageable treatment(s) for children and adult pa-
tients with sickle cell disease. Clinical trials have provided
Table 2 Mean (±sd) hematological parameter values of omega-3 fatty acid treated, hydroxyurea treated and untreated patients
(HbSS) and healthy controls
Omega-3 FA Treated Patients Untreated patients HU Treated Healthy Controls
Hb (g/l) 75.6 ± 16.2*** 75.9 ± 10.3+++ 79.5 ± 10.3 126.0 ± 10.9
HCt 22.9 ± 4.7*** 22.9 ± 3.0+++ 23.8 ± 2.8 38.0 ± 3.5
RBC 2.8 ± 0.7*** 2.7 ± 0.5+++ 2.8 ± 0.6 4.6 ± 0.5
MCV (fl) 84.3 ± 8.6 86.5 ± 7.1 87.8 ± 11.6 82.3 ± 4.7
MCH (pg) 27.9 ± 3.4 28.6 ± 3.0 29.5 ± 4.4 27.6 ± 1.9
MCHC 33.3 ± 2.0 33.1 ± 1.4 33.4 ± 0.9 33.5 ± 1.5
PLT 489.5 ± 121.1*** 533.6 ± 98.7+++ 414.5 ± 109.9× 330.3 ± 72.5
WBC 12.4 ± 4.3*** 13.3 ± 3.4+++ 13.6 ± 3.7 6.3 ± 1.3
***p < 0.001 Omega 3 treated versus healthy controls
++p < 0.01, +++p < 0.001 Untreated patients versus healthy controls
xp < 0.05, HU treated versus untreated patients
Awoda et al. BMC Hematology  (2017) 17:18 Page 4 of 7evidence that omega-3 fatty acids are effective in reducing
frequency and severity of vaso-occlusive episodes, severe
anemia, blood transfusion rate, markers of inflammation
and oxidative stress [17–21]. In the current study, patients
treated with omega-3 showed a significant reduction in D-
dimer. The findings of this study indicate that treatment
with omega-3 may partially ameliorate SCD-associated
coagulopathy.
The SCD patients and healthy controls who participated
in this study were homogenous with respect to ethnicity
and socio-economic background and the patients received
similar quality of care under regular management proto-
cols. The samples were collected in one clinic and at the
same time of the year. Therefore, the observed findings
are likely to be due to the effect of intervention with
omega-3 fatty acids or hydroxyurea treatment rather than
of extraneous confounding factors.
Consistent with previous studies, both the omega-3 fatty
acid treated and untreated patients had elevated steady
state white blood cell and platelet counts confirming that
sickle cell disease is a chronic inflammatory disorder [22].
Similarly, Tomer et al. [18] have reported that treatment
with omega-3 fatty acids do not effect significantly the
blood cell count, MCV or MCHC.
There is evidence which indicates that HU mediates its
beneficial effects in SCD, partially, by lowering leukocyte,
reticulocyte and platelet counts [23]. In the current study,Table 3 Mean (±sd) coagulation profile parameter values of
omega-3 fatty acid and hydroxyurea treated and untreated
sickle cell patients (HbSS) and healthy contols
Omga-3 treated untreated HU treated Healthy controls
PT (sec) 17.2 ± 1.8††† 31.3 ± 11.1+++ 18.2 ± 1.8xxx 14.5 ± 0.7
aPTT (sec) 38.3 ± 4.2††† 57.0 ± 11.3+++ 42.8 ± 2.7xxx 37.0 ± 3.8
INR 1.2 ± 0.14††† 2.3 ± 0.90+++ 1.3 ± 0.12xxx 1.01 ± 0.05
†††p < 0.001 omega-3 treated versus untreated patients
+++p < 0.001 untreated patients versus healthy controls
xxxp < 0.001 HU treated versus untreated patientsHU treatment reduced platelet count significantly but had
no noticeable effect on WBC. This unexpected effect of
HU on WBC among Sudanese children with SCD might
be a reflection of the fact that HU is generally being ad-
ministered mostly to the severely ill children with SCD
[24], or a response peculiar to Sudanese SCD patients that
warrant further research.
The PT, aPTT and INR levels of the untreated patients
were significantly higher than the n-3 fatty acid and
hydroxyurea treated groups. Similar findings have been
observed on Americans [25] and Nigerians children [26]
and adult Jamaicans [6] with sickle cell disease. The
prolongation of PT in the adult patients was not as re-
markable as in the children. In contrast, another study
investigated 17 subjects did not find a difference in
mean PT between SCD and healthy children [27].
These controversial findings might be a reflection of
the study small sample size.Fig. 1 Plasma D-dimer levels of omega-3 fatty acid treated,
hydroxyurea treated and untreated patients with homozygous
sickle cell disease (HbSS)
Fig. 2 Plasma Protein C levels of omega-3 fatty acid treated,
hydroxyurea treated and untreated patients with homozygous sickle
cell disease (HbSS) .*There were no significant differences (p > 0.05)
between the HbSS untreated, HbSS HU treated and HbSS omega-3
treated
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dren with SCD is not fully understood. It is suggested that
impaired liver function [25] and depletion of coagulation
factors [28] play a role in the prolongation process. How-
ever, it is worth pointing out that a relationship between
an abnormal liver function and coagulation prolongation
is yet to be established.
In contrast to the findings of the current study, high
omega-3 fatty acid intake did not have a significant effect
on PT and aPTT in adult patients with sickle cell diseaseFig. 3 Plasma Protein S levels of omega-3 fatty acid treated,
hydroxyurea treated and untreated patients with homozygous sickle
cell disease (HbSS). *There were no significant differences (p > 0.05)
between the HbSS untreated, HbSS HU treated and HbSS omega-3
treated[18], and in adult carcinoma patients undergoing elective
surgery [29]. The subjects in the latter two studies,
[18, 29], were adults from different ethnic background
clinical complications and normal coagulation parameter
values at baseline. In addition, the n-3 fatty acids compos-
ition of the oil/supplement used in these two studies were
different from the high DHA capsules given to the chil-
dren in the current study. The observed reduction of
coagulation parameters in treated SCD patients in this
study could be the result of increased availability of the
coagulation factors and the possible concomitant reduc-
tion in coagulation activation that could surpass its
potential detrimental hypo-coagulant effect [30, 31]. HU
treatment had a similar effect as n-3 fatty acids on PT and
aPTT suggesting that children with abnormal coagulation
profile are responsive to either therapy.
The low level steady-state proteins C and S in the Su-
danese children with SCD, which agrees with previous
findings [6, 32], is in line with the hypothesis that the
chronic activation of both the inflammatory and coagu-
lant pathways in SCD are partially due to the disease
associated down regulation of anti-coagulant pathway
[33]. Protein C, activated by thrombin in the presence
of protein S, inhibits the clotting ability of factor V and
VIII [34]. The underlying cause of the natural anti-
coagulant deficiency is yet to be elucidated. However, it
has been generally attributed to the known SCD-
associated hemostatic abnormalities and hepatic dys-
function [27]. An earlier study [35] reported a decrease
in proteins C in children with sickle cell disease treated
with hydroxyurea. That study included 11 children, 5 of
them were homozygous SCD patients. The discrepancy
of HU effect on proteins C and S between this study
and the previous study could be due to the fact that
Koc et al. study [35] was relatively underpowered to de-
tect the true HU effect on natural anti-coagulant
system.
Despite the observed improvement in coagulation
parameters and hypercoagulable state, treatment with
n-3 fatty acids did not result in a significant change
on the level of the natural anti-coagulant proteins C
and S. These findings may indicate that the liver role
on low natural anticoagulant in SCD might outweigh
the effect of over-consumption due to SCD-associated
hypercoagulable state.
The high levels of D-dimer in patients in the current
study confirm that hypercoagulability state is one of the
major elements of pathophysiology of the disease [33, 36].
Previous studies have reported that omega-3 fatty acid
intake is inversely associated with the level of fibrino-
gen, factor VIII and von Willebrand factor (VWF) [37]
and D-dimer [18]. Consistent with the latter study, the
current investigation demonstrates high DHA omega-3
fatty acid, but not HU, treatment reduces plasma D-dimer
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dimer by omega-3 fatty acids has implications for clinical
management of patients because plasma D-dimer level is
associated with a history of stroke in SCD [36].
This study did not attempt to elucidate the mechan-
ism through which omega-3 fatty acids, particularly
DHA and EPA, mediate their anti-coagulant effect.
Nevertheless, it is well established that some of the
metabolites of these fatty acid are antithrombotic,
antiaggregatory, antiinfalammrory and vasodilatory.
EPA by competing with arachidonic acid (AA) for cy-
clooxygenase and lipooxygenase enzymes [38] inhibits
the synthesis of the prothrombotic proaggregatory,
pro-inflammatory and vasoconstrictor metabolites of
AA. Recent animal and human studies suggest that
DHA is more potent anti-aggregatory agent than EPA
at high doses [39–41]. Interestingly, studies in SCD
have demonstrated that endothelial tissue factor ex-
pression is specifically dependent upon the nuclear
factor-kappa B (NFκB) component of blood mono-
nuclear cells [42]. Our group and others have shown
that treatment with high DHA omega-3 fatty acid was
associated with down regulation of NFκB gene expres-
sion in mononuclear cell and amelioration of SCD-
associated chronic inflammatory state [20, 43]. Hence,
it is justifiable to attribute the observed improvements
in the patient’s hypercoagulable state after high DHA
intervention to its suppressive effect on NFκB gene
expression and partial resolution of the chronic in-
flammatory state [44].
Besides the limitations of the observational studies,
the current study did not assess liver function in order
to have a better understanding of the observed abnor-
malities of coagulation system and the responses to
HU and omega-3 treatments. In addition, the effect of
omega-3 fatty acids and HU treatments on markers of
thrombin generation such as prothrombin fragment
F1, 2 and thrombin-anti-thrombin complexes, was not
investigated. Due to the fact that only patients above
10 years of age are treated with HU and generally
small fraction of patients were treated with HU in
Sudan, we did not manage to recruit enough number
of patients on HU matched by age and gender.
Conclusion
In conclusion, this study provides an evidence that
Sudanese children with sickle cell disease have an
abnormal coagulating profile which characterized by
prolonged PT and aPTT compared to heathy controls.
These two parameters were significantly reduced by
treatment with either HU or omega-3 fatty acids. With
the exception of the D-dimer, treatment with neither
omega-3 fatty acids nor HU resulted in a significant
change in markers of coagulation compared to theuntreated group. To elucidate the putative effects of
omega-3 fatty acids on SCD-associated coagulopathy, a
well-designed, prospective, randomized trial with an
extended panel of hemostaticis is warranted.
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